abnormal cervical cancer
Number 3
HKCOG Guidelines
Revised
November 2008
Guidelines on the Management of
Abnormal Cervical Cytology published by The Hong Kong College of Obstetricians and Gynaecologists
A Foundation College of Hong Kong Academy of Medicine
1 INTRODUCTION
The Guidelines on the Management of
Abnormal Cervical Cytology was revised in
2002 because of the revision of the Bethesda
System in 2001 and the introduction of HPV testing in the management of atypical squamous cells. This revision is based on new information being available, including the
ASC-US/LSIL Triage Study (ALTS) and the use of HPV testing as an adjunct in cervical cytology. In this guideline, HPV testing refers to testing for high-risk HPV types (1,2,3).
In this revision, the recommendations for atypical squamous cells (ASC) and low-grade squamous intraepithelial lesion (LSIL) are essentially unchanged, except in special populations such as adolescents, pregnant women, immunocompromised women and postmenopausal women. The management in these categories is being updated, such as adopting a more conservative approach with repeat cytology rather than immediate colposcopy in adolescents unless high-grade intraepithelial lesions (HSIL) are encountered.
There are minor modifications for management for HSIL and atypical glandular cells (AGC).
The use of HPV testing has been expanded, such as as an adjunct to cervical cytology screening in women aged 30 years and older.
when it forms part of an organized programme of screening (4).
2.3
3 TARGET POPULATION AND SCREENING
INTERVAL
3.1
2 RATIONALE FOR CERVICAL SCREENING
2.1
Cervical carcinoma, which is largely preventable, still affects 376 women and causes the death of 126 women in Hong
Kong in the year of 2005 according to
Hong Kong Cancer Registry. It is the 9th commonest malignancy in females and ranks 9th as a cause of cancer death in females in the year of 2005.
2.2
Cervical cytology screening
HKCOG Guidelines
Revised
November 2008
Guidelines on the Management of
Abnormal Cervical Cytology published by The Hong Kong College of Obstetricians and Gynaecologists
A Foundation College of Hong Kong Academy of Medicine
1 INTRODUCTION
The Guidelines on the Management of
Abnormal Cervical Cytology was revised in
2002 because of the revision of the Bethesda
System in 2001 and the introduction of HPV testing in the management of atypical squamous cells. This revision is based on new information being available, including the
ASC-US/LSIL Triage Study (ALTS) and the use of HPV testing as an adjunct in cervical cytology. In this guideline, HPV testing refers to testing for high-risk HPV types (1,2,3).
In this revision, the recommendations for atypical squamous cells (ASC) and low-grade squamous intraepithelial lesion (LSIL) are essentially unchanged, except in special populations such as adolescents, pregnant women, immunocompromised women and postmenopausal women. The management in these categories is being updated, such as adopting a more conservative approach with repeat cytology rather than immediate colposcopy in adolescents unless high-grade intraepithelial lesions (HSIL) are encountered.
There are minor modifications for management for HSIL and atypical glandular cells (AGC).
The use of HPV testing has been expanded, such as as an adjunct to cervical cytology screening in women aged 30 years and older.
when it forms part of an organized programme of screening (4).
2.3
3 TARGET POPULATION AND SCREENING
INTERVAL
3.1
2 RATIONALE FOR CERVICAL SCREENING
2.1
Cervical carcinoma, which is largely preventable, still affects 376 women and causes the death of 126 women in Hong
Kong in the year of 2005 according to
Hong Kong Cancer Registry. It is the 9th commonest malignancy in females and ranks 9th as a cause of cancer death in females in the year of 2005.
2.2
Cervical cytology screening